Revival Healthcare Capital led the financing round. Distalmotion said in a news release that the funds reinforce the confidence of its existing investors.
The company intends to use the funds raised to support its Dexter surgical robotic platform. Currently in day-to-day clinical use in Europe, Dexter treats patients across complex and high-volume procedure types. That includes general surgery, gynecology and urology.
Distalmotion aims for the funds to pave the way for FDA approval, plus continued acceleration of clinical experience in Europe.
“Dexter allows for ‘on-demand robotics’ and gives surgeons access to the benefits of both robotic and laparoscopic surgery, enabling best-in-class minimally invasive care for the patients,” said Distalmotion CEO Michael Friedrich. “Surgeons can choose to operate entire procedures robotically, or they can leverage the ability to easily switch between the robotic and laparoscopic modalities to perform specialized tasks such as stapling with their preferred and trusted instruments.
“Surgeons are therefore empowered with choice and control.”
More about the Distalmotion Dexter platform
Distalmotion and Dexter featured on MassDevice’slist of eight surgical robotics companies you need to know. Read more about the outlook for surgical robotics in the coming years HERE.
Dexter easily integrates into clinical practice, the company says. It requires no additional infrastructure, fits into every clinical setting and features mobility for sharing across departments. Institutions can then scale robotics programs across surgical disciplines, enhancing the standard of care.
“Dexter delivers what surgeons need most for when it matters most. It provides advanced dexterity for complex surgical steps such as suturing, dissection and working in confined spaces,” said Dr. Dieter Hahnloser, head of colorectal surgery at Lausanne University Hospital, who performed the first general surgery procedure with Dexter in 2021. “Dexter’s open platform allows surgeons to choose the best-in-class tools and technology for each step of the procedure. It is compatible with all 3D laparoscopes which allows surgeons to leverage current and future imaging innovations.”
Rick Anderson, chair of Revival and Distalmotion, said the financing “sets the stage” for the company’s next steps. He added that the company’s mission is to expand adoption of Dexter to hospitals worldwide.
“We are very proud of our global leadership team’s accomplishment to bring Distalmotion’s technology to the market and to set the stage for the company’s entry into the U.S. market,” Anderson said.
